Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
HUGO Series 🌟
HUGO-GT™ (Humanized Genomic Ortholog)
HUGO-Ab™ (Humanized Genomic Ortholog for Antibody)
MouseAtlas Model Library
Flash Sales
Research Models
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
Cell Line Models
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
iPSC Cell Line Product Catalog
AAV Standard Product Catalog
Services
Preclinical Efficacy
Neuroscience
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Models
Human Immune System (HIS) Mouse Model
Metabolic & Cardiovascular Diseases
Anti-Obesity
Autoimmune & Inflammatory
Asthma
Genetically Engineered Animals
Knockout Mice
Transgenic Mice
Knockin Mice
Knockout Rats
Knockin Rats
Transgenic Rats
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Breeding & Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Modalities
Gene Therapy
AI-Powered AAV Discovery
Oligonucleotide Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell Cell Culture
About Us
Corporate Overview
Facility Overview
Animal Health & Welfare
Health Reports
Our Team
Our Partners
Careers
Contact Us
Login
IDEAS TO IND — YOUR PATHWAY TO DISCOVERY
ONE PARTNER
EVERY STAGE
20
Years of Genetic Innovation
10,700
Global Bioscience Partners
50,000
Mouse & Rat Models Delivered
16,500
SCI Journal Citations
250,000
SPF Animals in AAALAC-Accredited Facilities
Animal
Innovative Solutions & Trusted Products
Genetically Engineered Animals
Cyagen provides knockout, knockin, and transgenic models with high genetic precision to support research in genetics, pharmacology, and disease modeling.
Comprehensive Research Models
Our humanized, knockout, and disease-specific mice closely mimic human conditions, empowering your preclinical studies from rare diseases to oncology.
Custom Cell Lines
Cyagen delivers custom iPSC, knockout, and knockin cell lines for genetic studies, drug screening, and therapeutic development.
Virus Packaging Solutions
We offer AAV, lentivirus, and adenovirus packaging for gene therapy, vaccine R&D, and gene editing applications.
Antibody Therapy CRO Services
Cyagen accelerates antibody drug discovery with fully human antibody mice and AI-powered screening, supporting you from discovery to validation.
Animal Quality
We uphold the highest standards in animal welfare and qualty in our AAALAC-accredited faciities, ensuring ethical research practices.
Special Promotions & Discounts
See All Promotions
special offer
Flash Drop — Ready-to-Ship KO/cKO Mice
Unlock fast, budget-friendly access to KO/cKO mouse lines from Cyagen’s MouseAtlas. We will release exclusive flash deals on selected knockout and conditional knockout strains in real-time– helping you launch or expand your in vivo studies without long lead times or high upfront costs.
Explore
Your Partners in Preclinical Progress
Pioneering life science advancements to deliver real-world health solutions.
Our Solutions: Integrated preclinical services, including:
  • ● Cell & animal model development and viral packaging.
  • ● Expert-led preclinical studies.
Your Outcome: Seamlessly translating innovative research into actionable results and successful IND applications.
Citation Database
Molecular Therapy: Methods & Clinical Development, March, 2025
Intracranial AAV administration dose-dependently recruits B cells to inhibit the AAV redosing
【Other】
Gut, February, 2025
E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression
【Other】
Cell Death & Disease, February, 2025
Mcm5 mutation leads to silencing of Stat1-bcl2 which accelerating apoptosis of immature T lymphocytes with DNA damage
【Other】
Molecular Therapy, February, 2025
Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer
【Other】
Resource Library
BLOG & INSIGHTS
More Insights
Hemophilia Gene Therapy & Next-Gen Treatments: F8/F9 Humanized Mouse Models for Preclinical Validation
Hemophilia Gene Therapy & Next-Gen Treatments: F8/F9 Humanized Mouse Models for Preclinical Validation
Discover how F8/F9 humanized mouse models accelerate the validation of next-gen hemophilia treatments, including gene therapy and antibody mimetics. Cyagen offers specialized models for Hemophilia A, B, and C research, crucial for overcoming clinical challenges and achieving functional cures.
June 03, 2026
Read Now
UPCOMING EVENT
More
FENS Forum 2026
FENS Forum 2026
Cyagen will be attending FENS Forum 2026 from July 6–10 in Barcelona, Spain, where our experts will be on hand to discuss your drug development plans and introduce you to our advanced neurological mouse models and comprehensive preclinical research services. We look forward to connecting with you!
Schedule Meeting
WEBINAR
More
Beyond the mouse: Accelerating Drug Discovery for Obesity & T2D with HUGO-GT™
Beyond the mouse: Accelerating Drug Discovery for Obesity & T2D with HUGO-GT™
Traditional preclinical models face a 92% clinical failure rate. This webinar introduces Cyagen’s HUGO-GT™ platform to bridge this translational gap. Discover how full-length humanized models empower evaluating therapies like siRNAs for obesity and cardiovascular diseases. Attendees will review real pharmacodynamic data and explore comprehensive end-to-end CRO services.
Schedule Meeting
FEATURED NEWS
Taconic and Cyagen Collaborate to Streamline Access to Preclinical Mouse and Rat Models
August 04, 2025
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Models
HUGO-Ab™ (Humanized Genomic Ortholog for Antibody)HUGO-GT™ (Humanized Genomic Ortholog)MouseAtlas Model LibraryResearch Models
Services
NeuroscienceOphthalmologyOncologyMetabolic & Cardiovascular DiseasesAutoimmune & Inflammatory
About Us
Corporate OverviewFacility OverviewAnimal Health & WelfareHealth ReportsOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research